DDInter1631 DDInter1331
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Olodaterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Olodaterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norfloxacin
Olodaterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Olodaterol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Olodaterol {u} may lead to a major life threatening interaction when taken with {v} Cocaine
Olodaterol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Olodaterol may lead to a major life threatening interaction when taken with Macimorelin
Olodaterol may lead to a major life threatening interaction when taken with Cocaine